Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00661960 · ClinicalTrials.gov registry record · NA
Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy
A NA study, sponsored by University of California, Davis.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT00661960 is a NA study that has completed, run by University of California, Davis. The registered enrollment target is 25 participants.
The verdict
NCT00661960, a NA study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
This research is being done to study how the immune system in the small intestine improves after taking antiretroviral (anti-HIV) medications. The main purpose is to measure the increase in the numbers of immune cells in the intestine to see if one type of HIV medication gives different results than other types of HIV medications.
Interventions
- DRUG efavirenz
- DRUG raltegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-03 |
| Est. Completion | 2011-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00661960
The ClinicalTrials.gov registry entry for NCT00661960 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which efavirenz is the first listed.
NCT00661960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00661960 about?
NCT00661960 is a clinical study titled "Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy". This research is being done to study how the immune system in the small intestine improves after taking antiretroviral (anti-HIV) medications. The main purpose is to measure the increase in the numbers of immune cells in the intestine to see if one type of HIV medication gives different results than...
What is the current status of trial NCT00661960?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2008-03. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00661960?
The interventions under investigation include: efavirenz (DRUG), raltegravir (DRUG).
Who is sponsoring clinical trial NCT00661960?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.